Payment overview · 2025
General Payments
$3,517.78
99 reported records · 22 companies
Healthcare provider profile · identity verified
Amit Guttigoli, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · DUNCANVILLE, TX · NPI 1760417026
Verified facts
What the public records show
CMS Open Payments records show Amit Guttigoli, MD received $3,517.78 in general payments during 2025 across 99 reported records.
Boston Scientific Corporation accounted for 40.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 390 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,422.05 | 40.4% | 42 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $726.60 | 20.7% | 10 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $173.75 | 4.9% | 10 | 2025 |
| AOP Health US, LLC | Unresolved — no canonical attribution shown | $150.14 | 4.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $132.99 | 3.8% | 6 | 2025 |
| EBR SYSTEMS, INC. | Unresolved — no canonical attribution shown | $128.54 | 3.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $125.43 | 3.6% | 4 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $125.00 | 3.5% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $102.69 | 2.9% | 4 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $79.95 | 2.3% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $58.65 | 1.7% | 2 | 2025 |
| Vital Connect, Inc | Unresolved — no canonical attribution shown | $52.98 | 1.5% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$51.23 | 1.5% | 3 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $37.89 | 1.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.77 | 0.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.90 | 0.6% | 1 | 2025 |
| AltaThera Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $19.17 | 0.5% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $18.51 | 0.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.48 | 0.5% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $18.46 | 0.5% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $16.59 | 0.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.01 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,508.76 | 98 |
| Travel and Lodging | $9.02 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $701.22 | 15 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $506.90 | 7 | 2025 |
Source payment records
|
|||||
| Rhythmia Mapping System Normalized: rhythmia mapping system |
Device | Boston Scientific Corporation | $276.28 | 7 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $173.75 | 10 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $170.00 | 1 | 2025 |
Source payment records
|
|||||
| Rapiblyk Normalized: rapiblyk |
Drug | AOP Health US, LLC | $150.14 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $132.99 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $125.43 | 4 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $111.70 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $102.69 | 4 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $91.98 | 3 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $79.95 | 2 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $69.39 | 4 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $58.65 | 2 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $56.35 | 2 | 2025 |
Source payment records
|
|||||
| VITALPATCH RTM Normalized: vitalpatch rtm |
Device | Vital Connect, Inc | $52.98 | 3 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $51.23 | 3 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $49.70 | 2 | 2025 |
Source payment records
|
|||||
| LATITUDE Communicator Power Supply Normalized: latitude communicator power supply |
Device | Boston Scientific Corporation | $44.38 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $39.29 | 4 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $37.89 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| Sotalol Hydrochloride Normalized: sotalol hydrochloride |
Drug | AltaThera Pharmaceuticals LLC | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ EXTRA Normalized: aquacel ag extra |
Device | ConvaTec Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| General - CRM_CRM Normalized: general crm crm |
Device | Boston Scientific Corporation | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| Event Normalized: event |
Device | Philips North America LLC | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| ENHANCE Transcarotid Peripheral Access Kit Normalized: enhance transcarotid peripheral access kit |
Device | Boston Scientific Corporation | $14.19 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 390 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
110 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
390 | 108 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 390 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 295 | 109 |
| Amiodarone Hcl | Amiodarone Hcl | 262 | 91 |
| Furosemide | Furosemide | 218 | 81 |
| Carvedilol | Carvedilol | 203 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 158 | 57 |
| Entresto | Sacubitril/Valsartan | 110 | 28 |
| Losartan Potassium | Losartan Potassium | 107 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 28 |
| Xarelto | Rivaroxaban | 61 | 20 |
| Lisinopril | Lisinopril | 60 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | 24 |
| Flecainide Acetate | Flecainide Acetate | 55 | 14 |
| Potassium Chloride | Potassium Chloride | 44 | 13 |
| Atorvastatin Calcium | Atorvastatin Calcium | 43 | 15 |
| Farxiga | Dapagliflozin Propanediol | 43 | 15 |
| Multaq | Dronedarone Hcl | 41 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 17 |
| Digoxin | Digoxin | 39 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 31 | 11 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Omeprazole | Omeprazole | 23 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,517.78 · 99 records | Boston Scientific Corporation | ACCOLADE SR, AQUACEL AG+ EXTRA, AREXVY, AVEIR, Assure WCD, BIOMONITOR, Barostim Neo System, CARDIVA VASCADE MVP VVCS 6-12F, CARTO 3, COREVALVE EVOLUT R, ELIQUIS, EMBLEM MRI S-ICD, ENHANCE Transcarotid Peripheral Access Kit, Event, FARAPULSE, GALLANT, General - CRM_CRM, General - Therapies, INSPIRE, JOT DX, Kerendia, LATITUDE Communicator Power Supply, LEQVIO, LUX-Dx Insertable Cardiac Monitor, LifeVest, Rapiblyk, Rhythmia Mapping System, SHINGRIX, Sotalol Hydrochloride, VERQUVO, VISTASEAL, VITALPATCH RTM, WATCHMAN FLX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error